SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Drop in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 67,700 shares, a decline of 42.8% from the January 31st total of 118,400 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily volume of 127,400 shares, the days-to-cover ratio is currently 0.5 days.

SAB Biotherapeutics Stock Performance

SABS stock traded up $0.02 during midday trading on Friday, hitting $1.71. The company had a trading volume of 54,239 shares, compared to its average volume of 155,480. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. SAB Biotherapeutics has a 52 week low of $1.60 and a 52 week high of $6.30. The stock’s 50 day moving average price is $2.93 and its 200 day moving average price is $3.00.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp bought a new stake in SAB Biotherapeutics in the fourth quarter valued at approximately $43,000. Kovitz Investment Group Partners LLC bought a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $52,000. Diadema Partners LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $114,000. Geode Capital Management LLC raised its holdings in shares of SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after acquiring an additional 12,692 shares in the last quarter. Finally, HB Wealth Management LLC raised its holdings in shares of SAB Biotherapeutics by 118.6% during the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after acquiring an additional 128,800 shares in the last quarter. Institutional investors own 7.82% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on SABS shares. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SAB Biotherapeutics has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.